Michael Tocco

596 total citations
62 papers, 453 citations indexed

About

Michael Tocco is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, Michael Tocco has authored 62 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Psychiatry and Mental health, 9 papers in Clinical Psychology and 7 papers in Pharmacology. Recurrent topics in Michael Tocco's work include Bipolar Disorder and Treatment (26 papers), Schizophrenia research and treatment (13 papers) and Attention Deficit Hyperactivity Disorder (8 papers). Michael Tocco is often cited by papers focused on Bipolar Disorder and Treatment (26 papers), Schizophrenia research and treatment (13 papers) and Attention Deficit Hyperactivity Disorder (8 papers). Michael Tocco collaborates with scholars based in United States, India and Germany. Michael Tocco's co-authors include Zaldy S. Tan, Alexa Beiser, Peter W.F. Wilson, Douglas P. Kiel, Sudha Seshadri, Ralph B. D’Agostino, Philip A. Wolf, Antony Loebel, Lisa Tabor Connor and Loraine K. Obler and has published in prestigious journals such as Neurology, Journal of the American Academy of Child & Adolescent Psychiatry and Schizophrenia Bulletin.

In The Last Decade

Michael Tocco

60 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Tocco United States 9 226 157 78 63 53 62 453
Fumiko Irie Australia 7 207 0.9× 227 1.4× 45 0.6× 66 1.0× 21 0.4× 9 488
Chiaki Ikejima Japan 11 232 1.0× 209 1.3× 97 1.2× 54 0.9× 27 0.5× 15 502
Kathryn Davis United States 18 290 1.3× 273 1.7× 171 2.2× 113 1.8× 73 1.4× 36 868
Amy L. Alderson United States 8 147 0.7× 208 1.3× 38 0.5× 69 1.1× 101 1.9× 9 688
Anne Rita Øksengård Norway 13 169 0.7× 93 0.6× 48 0.6× 105 1.7× 57 1.1× 20 492
B. Wasiak Poland 9 235 1.0× 250 1.6× 41 0.5× 52 0.8× 58 1.1× 13 547
V. Canonico Italy 9 212 0.9× 128 0.8× 41 0.5× 60 1.0× 71 1.3× 27 635
Carlo Baraldi Italy 18 566 2.5× 167 1.1× 69 0.9× 69 1.1× 21 0.4× 46 765
S. Bakchine France 14 210 0.9× 173 1.1× 52 0.7× 74 1.2× 150 2.8× 37 719

Countries citing papers authored by Michael Tocco

Since Specialization
Citations

This map shows the geographic impact of Michael Tocco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tocco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tocco more than expected).

Fields of papers citing papers by Michael Tocco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tocco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tocco. The network helps show where Michael Tocco may publish in the future.

Co-authorship network of co-authors of Michael Tocco

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Tocco. A scholar is included among the top collaborators of Michael Tocco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Tocco. Michael Tocco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Semwal, Monika, Gideon Aweh, S. Duke Han, et al.. (2024). Healthcare Resource Use and Cost Associated with Negative Symptoms of Schizophrenia. CNS Spectrums. 29(5). 504–505. 1 indexed citations
3.
Tocco, Michael & Yongcai Mao. (2024). Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode. Journal of Clinical Psychopharmacology. 44(4). 345–352. 1 indexed citations
4.
Goldberg, Joseph F., et al.. (2023). The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression. The Journal of Clinical Psychiatry. 84(4). 3 indexed citations
5.
Tocco, Michael, et al.. (2023). Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression. CNS Spectrums. 28(6). 680–687. 3 indexed citations
6.
7.
Hanania, Nicola A., Abebaw Mengistu Yohannes, Ayca Ozol-Godfrey, et al.. (2021). Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. International Journal of COPD. Volume 16. 865–875. 4 indexed citations
8.
DelBello, Melissa P., et al.. (2021). Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. Journal of Child and Adolescent Psychopharmacology. 31(7). 494–503. 7 indexed citations
9.
Niu, Xiaoli, Carole Dembek, Kimberly K. Laubmeier, et al.. (2021). Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data. Current Therapeutic Research. 94. 100629–100629. 4 indexed citations
10.
Mattingly, Gregory W., Peter Haddad, Michael Tocco, et al.. (2020). Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. BMC Psychiatry. 20(1). 199–199. 14 indexed citations
11.
Miller, Brian J., Cynthia Siu, Michael Tocco, et al.. (2020). Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive Psychiatry. 102. 152195–152195. 5 indexed citations
12.
Singh, Manpreet K., et al.. (2020). Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. 30(10). 590–598. 10 indexed citations
13.
Tocco, Michael, et al.. (2020). Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. CNS Spectrums. 26(6). 614–624. 8 indexed citations
14.
Tocco, Michael, et al.. (2020). P.325 Effect of lurasidone on manic symptoms and treatment-emergent mania in adult and pediatric populations with bipolar depression. European Neuropsychopharmacology. 40. S188–S189. 1 indexed citations
15.
Raison, Charles L., et al.. (2019). C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain Behavior and Immunity. 84. 269–274. 12 indexed citations
16.
Singh, Manpreet K., Robert Goldman, Michael Tocco, et al.. (2017). 5.50 Symptom Improvement Associated With Lurasidone Treatment of Children and Adolescents With Bipolar I Depression: Results of a Short-Term Placebo-Controlled Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 56(10). S271–S272. 1 indexed citations
17.
18.
Yaffe, Kristine, Michael Tocco, Ronald C. Petersen, et al.. (2012). The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials. Alzheimer s & Dementia. 8(3). 237–242. 19 indexed citations
19.
Tocco, Michael, Suzanne Hendrix, M. L. Miller, Vojislav Pejović, & Hamish Graham. (2012). P3‐380: Effects of extended‐release memantine (28 mg, once daily) on language and communication abilities in a randomized trial of patients with moderate‐to‐severe Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_16). 1 indexed citations
20.
Connor, Lisa Tabor, Loraine K. Obler, Michael Tocco, Patricia M. Fitzpatrick, & Martin L. Albert. (2001). Effect of Socioeconomic Status on Aphasia Severity and Recovery. Brain and Language. 78(2). 254–257. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumiko Irie Breakdown of academic impact, for papers by Chiaki Ikejima Breakdown of academic impact, for papers by Kathryn Davis Breakdown of academic impact, for papers by Amy L. Alderson Breakdown of academic impact, for papers by Anne Rita Øksengård Breakdown of academic impact, for papers by B. Wasiak Breakdown of academic impact, for papers by V. Canonico Breakdown of academic impact, for papers by Carlo Baraldi Breakdown of academic impact, for papers by S. Bakchine
Rankless by CCL
2026